Baltimore, MD
,
USA
·
North America
SR One is a Philadelphia-based independent life sciences venture capital firm founded in 1985 as the corporate venture arm of GlaxoSmithKline (GSK) and subsequently spun out as a fully independent firm in 2020. The firm manages more than $1 billion in assets and invests from seed through Series B stages with initial checks from $5 million to $25 million. Portfolio companies include CytomX Therapeutics, the clinical-stage company developing conditionally activated biologic cancer therapies; Goldfinch Bio, the precision medicine company developing treatments for kidney diseases; Imago BioSciences, acquired by Bristol-Myers Squibb for $1.35 billion; and Passage Bio, the gene therapy company that completed a Nasdaq IPO. Beyond its original investments, the portfolio includes additional clinical-stage biopharmaceutical companies.
Know when they open it, which slides they read, and when to follow up.
Pitchwise turns every shared deck into a live intelligence feed.
